Tags: Drug.
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13 and is designed for the treatment of asthma and inflammatory diseases.Tralokinumab was discovered by Cambridge Antibody Technology as CAT-354 who took it through pre-clinical development. As of April 2012 it is being developed by MedImmune.